Transgenic Expression of Soluble Human CD5 Enhances Experimentally-Induced Autoimmune and Anti-Tumoral Immune Responses

Rafael Fenutria\textsuperscript{1,}*, Vanesa G. Martinez\textsuperscript{1,}*, Inês Simões\textsuperscript{1}, Jorge Postigo\textsuperscript{2}, Victor Gil\textsuperscript{3}, Mario Martínez-Florensa\textsuperscript{1}, Jordi Sintes\textsuperscript{4}, Rodrigo Naves\textsuperscript{5}, Kevin S. Cashman\textsuperscript{6}, José Alberola-Ila\textsuperscript{7}, Manel Ramos-Casals\textsuperscript{3}, Gloria Soldevila\textsuperscript{8}, Chander Raman\textsuperscript{5}, Jesús Merino\textsuperscript{2}, Ramón Merino\textsuperscript{2,9}, Pablo Engel\textsuperscript{4}, Francisco Lozano\textsuperscript{1,4,10*}

\textsuperscript{1} Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, \textsuperscript{2} Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain, \textsuperscript{3} Servei de Malalties Autoimmunes Sistèmiques, Hospital Clínic de Barcelona, Barcelona, Spain, \textsuperscript{4} Departamento de Biología Celular, Immunología e Neurociencias, Universitat de Barcelona, Barcelona, Spain, \textsuperscript{5} Departamento of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, \textsuperscript{6} Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, \textsuperscript{7} Oklahoma City, Oklahoma, United States of America, \textsuperscript{8} Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Distrito Federal, México, \textsuperscript{9} Instituto de Biomedicina y Biotecnología de Cantabria, Consejo Superior de Investigaciones Científicas-Universidad de Cantabria, SODERCAN, Santander, Spain, \textsuperscript{10} Servei d’Immunologia, Hospital Clínic de Barcelona, Barcelona, Spain

Abstract

CD5 is a lymphoid-specific transmembrane glycoprotein constitutively expressed on thymocytes and mature T and B1a lymphocytes. Current data support the view that CD5 is a negative regulator of antigen-specific receptor-mediated signaling in these cells, and that this would likely be achieved through interaction with CD5 ligand/s (CD5L) of still undefined nature expressed on immune or accessory cells. To determine the functional consequence of loss of CD5/CD5L interaction in vivo, a new transgenic mouse line was generated (shCD5\textsubscript{E}Tg), expressing a circulating soluble form of human CD5 (shCD5) as a decoy to impair membrane-bound CD5 function. These shCD5\textsubscript{E}Tg mice showed an enhanced response to autologous antigens, as deduced from the presentation of more severe forms of experimentally inducible autoimmune disease (collagen-induced arthritis, CIA; and experimental autoimmune encephalitis, EAE), as well as an increased anti-tumoral response in non-orthotopic cancer models (B16 melanoma). This enhancement of the immune response was in agreement with the finding of significantly reduced proportions of spleen and lymph node Treg cells (CD4\textsuperscript{+}CD25\textsuperscript{+}FoxP3\textsuperscript{+}), and of pentonental IL-10-producing and CD5\textsuperscript{+} B cells, as well as an increased proportion of spleen NKT cells in shCD5\textsubscript{E}Tg mice. Similar changes in lymphocyte subpopulations were observed in wild-type mice following repeated administration of exogenous recombinant shCD5 protein. These data reveal the relevant role played by CD5/CD5L interactions on the homeostasis of some functionally relevant lymphocyte subpopulations and the modulation of immune responses to autologous antigens.

Introduction

CD5 is a monomeric 67-kDa lymphocyte surface glycoprotein belonging to the scavenger receptor cysteine-rich superfamily (SRCR-SF) \cite{1,2}. This ancient and well conserved group of receptors includes both membrane-bound and/or secreted proteins involved in the development and the regulation of innate and specific immune responses \cite{3,4}. CD5 is expressed on thymocytes from early stages of their development, as well as on all mature peripheral T lymphocytes, and a subpopulation of peripheral B lymphocytes called B1a \cite{5}, with the highest expression levels found on T and B cells subsets with well-known regulatory/suppressor function (CD4+CD25+FoxP3+ Treg cells, and...
CD19+CD1d+HL-10+ Breg cells [6–8]. On the surface of all these lymphoid cells, CD5 is physically associated to the T- and B-cell antigen-specific receptor (TCR and BCR, respectively) [9], and it is therefore well positioned to modulate the intensity of antigen-driven lymphocyte activation and differentiation signals.

Indeed, CD5 possesses a relatively large cytoplasmic domain devoid of enzymatic activity but harboring potential tyrosine and serine/threonine phosphorylation motifs compatible with a function in signal transduction [10,11]. Engagement of CD5 may, however, result in different modulatory signals depending on the cell type analyzed and the maturation stage [12]. In mature T cells, CD5 was first considered as a co-stimulatory molecule for TCR receptor signaling [13,14], but later studies showed a role for this molecule as a negative regulator of TCR signaling in thymocytes [15] and BCR signaling in B1a cells [16]. The fact that negative regulation does not occur in the absence of the CD5 cytoplasmic domain suggests that this effect depends on intracellular interactions mediated through signaling effector molecules [17]. It should be noted here that although several candidates have been proposed (CD72, gp35-40, IgVH, gp150, and CD5 itself), no CD5 ligand has been independently verified to date [3].

Although CD5 is a transmembrane molecule, a soluble form of human CD5 (shCD5) can be generated in activated T lymphocytes as a result of proteolytic cleavage [18]. Low levels of shCD5 (in the pico/nanomolar range) have been identified in the serum of healthy individuals, with discrete increased expression of this form reported in some autoimmune disorders such as rheumatoid arthritis [19], primary Sjögren’s syndrome [20] and atopic dermatitis [21]. The functional relevance of sCD5 has not yet been elucidated; however, the fact that elevated levels of this protein have been found in certain autoimmune diseases suggests that sCD5 may be an indicator of chronic or exacerbated T cell activation, or alternatively, that it may play a role in the modulation of the immune response by interacting with the still uncharacterized endogenous CD5 ligand/s. Accordingly, affinity-purified shCD5 from pooled human sera was shown to bind a panel of different cell types of lymphoid (T and B), myeloid and epithelial origin. This cell binding pattern was identical to that panel of different cell types of lymphoid (T and B), myeloid and epithelial origin. This cell binding pattern was identical to that

Although CD5 is a transmembrane molecule, a soluble form of human CD5 (shCD5) can be generated in activated T lymphocytes as a result of proteolytic cleavage [18]. Low levels of shCD5 (in the pico/nanomolar range) have been identified in the serum of healthy individuals, with discrete increased expression of this form reported in some autoimmune disorders such as rheumatoid arthritis [19], primary Sjögren’s syndrome [20] and atopic dermatitis [21]. The functional relevance of sCD5 has not yet been elucidated; however, the fact that elevated levels of this protein have been found in certain autoimmune diseases suggests that sCD5 may be an indicator of chronic or exacerbated T cell activation, or alternatively, that it may play a role in the modulation of the immune response by interacting with the still uncharacterized endogenous CD5 ligand/s. Accordingly, affinity-purified shCD5 from pooled human sera was shown to bind a panel of different cell types of lymphoid (T and B), myeloid and epithelial origin. This cell binding pattern was identical to that panel of different cell types of lymphoid (T and B), myeloid and epithelial origin. This cell binding pattern was identical to that

In an attempt to investigate the role of sCD5 in the homeostasis of immune cell populations, as well as during the course of the immune response, we generated a transgenic mouse line expressing a soluble form of human CD5 under the transcriptional control of the SV40 promoter and the immunoglobulin μ heavy chain enhancer (shCD5EμTg mice). Our assumption was that shCD5 would work as a decoy receptor, which would likely block the interactions between CD5 and its ligand/s (CD5L) wherever they are and wherever they are expressed. This is possible because we have observed cross-reactivity between human CD5 and murine CD5L, as has also been described for the highly homologous receptor CD6 [18]. Therefore, the study of these mice might shed light on the consequences of this interaction and, since the effects of the human protein can be tested, might serve as a test bed for future clinical use of shCD5. A similar approach has already been used for the study of other molecules, such as CTLA-4 [25] and VEGF-3 [26]. It is shown here that shCD5EμTg mice exhibit alterations in lymphocyte subpopulations with a regulatory/suppressive function, which can be reproduced in normal non-transgenic mice after repeated administration of exogenous rshCD5. Moreover, the expression of circulating shCD5 appears to be immunologically relevant, since shCD5EμTg mice showed increased severity of experimentally induced autoimmune disorders, and slower tumor growth compared with non-transgenic littermates. The latter anti-tumoral effects were also reproduced by repeated administration of purified rshCD5 to non-transgenic mice. Therefore, our data support a role for CD5/CD5L interactions in the homeostasis of some lymphocyte populations with regulatory and/or effector function, while highlighting the potential use of targeting CD5 as an immunomodulatory strategy in cancer therapy.

Materials and Methods

Animals

In vivo studies were carried out under protocols approved by the Ethics Committee for Animal Research of the University of Barcelona (permits number 498/12, 505/12 and 507/12), and were carried out in compliance with the International League of Associations for Rheumatology Guide for the Care and Use of Laboratory Animals, University of Cantabria, and the National Institutes of Health and University of Alabama at Birmingham Institutional Animal Care and Use Committee guidelines. All efforts were made to minimize animal suffering.

Generation and genotyping of shCD5EμTg mice

The DNA sequence coding for the whole extracellular region of CD5 was amplified from the pHJAPRI-neo-CD5.P346top construct [18] and subcloned into Xhol-Apal restricted pIgHSV40s vector which contained the SV40 promoter and the immunoglobulin μ heavy chain enhancer (Eμ). This vector, termed pIgHSV40shCD5, was injected into fertilized eggs from a CBAxC57Bl/6 mixed background. Founder mice were back-crossed for 10 generations into the C57Bl/6 background. Non-transgenic littermates were used in all experiments. Transgenic mice were identified by PCR analysis of genomic DNA samples from ear punch specimens in a GeneAmp PCR System 2700 thermocycler (Applied Biosystems, USA). The cycling conditions were: 30 cycles of 5 min at 94°C, 1 min at 53°C, and 8 min at 72°C. The primers to detect the transgene were specific for the extracellular region of human CD5 (forward, 5’-TCACTCAAGGGCAGCCTCCTTC-3’; reverse, 5’-GAAGCTCTTCATGCTGAC-3’). Internal control amplification primers (forward, 5’-TCATCCAGGGCAACCTTCATGCT-3’; reverse, 5’-CGATGCTATGCTTAAGCATAGAC-3’); specific for the invariant chain II of MHC class II (LIEX) were also included. The resulting PCR products (450 and 130 bp, respectively) were separated in a 2% agarose gel and visualized in a G:Box system (SynGene, UK).

Production, purification and labeling of recombinant human proteins and mouse antibodies

The generation of expression constructs for recombinant soluble human CD5 and CD6 as well as their production and purification have been previously described [27,28].
Mouse monoclonal antibodies (mAb) to human CD5, Cris-1 and Leu-1, were obtained from Dr. Ramon Vilella (Hospital Clinic of Barcelona) and the American Type Culture Collection (Manassas, VA), respectively, and purified by affinity chromatography using HiTrap Protein G columns (GE Healthcare).

Bioinylation of recombinant proteins and mAbs was performed with EZ-Link PEO-maleimide–activated biotin (Pierce) following the manufacturer’s instructions.

ELISA assays

The circulating levels of shCD5 were quantified by sandwich ELISA. 96-well plates (Nunc Maxisorb, Denmark) were coated overnight (o/n) at 4°C with 2 μg/mL of Cris-1 mAb as capture antibody, and then blocked for 1 h at 37°C with 2% bovine serum albumin (BSA) in phosphate buffered saline (PBS). Neat mouse serum samples (100 μL) or serial dilutions of purified rshCD5, used as protein standard, were added to wells and incubated for 2 h at room temperature (RT). After washing three times with PBS 0.05% Tween 20 (PBS-T), 100 μL of 2 μg/mL of biotin-labeled Leu-1 mAb were added and incubated for 1 h at RT. Plates were washed again three times with PBS-T and incubated with horseradish peroxidase (HRP)-labeled streptavidin (Roche) for 30 min at RT. Color was developed in the plate using the ELISA Amplification System (Invitrogen, UK) and absorbance measured at 495 nm.

For detection of anti-human CD5 and CD6 mouse antibodies, ELISA plates were coated with TNP-p-BSA (3 μg/mL) in PBS. Once blocked with BSA, diluted mouse serum samples (100 μL) were added to the wells and incubated for 2 h at RT. After extensive washing with PBS-T, wells were incubated for 30 min at RT with HRP-labeled anti-mouse immunoglobulin antisera (Sigma). Color was developed in the plate by addition of TMB substrate (BD Biosciences, USA) and absorbance measured at 450 nm.

Levels of TNP-specific antibodies of different isotypes were determined by using ELISA plates coated o/n with TNP-p-BSA (3 μg/mL) in PBS. Once blocked with BSA, diluted 100 μL serum samples (1/500 for detection of IgM, and 1/10000 for all IgG isotypes) were added to the wells and incubated for 1 h at RT. Then, biotinylated sheep anti-mouse IgM, IgG1, IgG2a, IgG2b, IgG2c and IgG3 antiserum (Jackson ImmunoResearch Laboratories, USA) were incubated for 1 h at RT. After three washes with PBS-T, HRP-labeled streptavidin was added and the plates developed with TMB.

Immunoprecipitation and Western blot analysis of serum shCD5

Pooled sera from shCD5EU/Tg mice and non-transgenic littermates were sequentially precipitated to a final saturation of 20 and 70% ammonium sulfate. After extensive dialysis against PBS, the 70% protein precipitate was immunoprecipitated with Cris-1 mAb coupled CNBr-activated Sepharose (GE Healthcare) beads [18,29]. Immunoprecipitates were separated on 10% agarose gels under non-reducing conditions and then Western blotted with biotin-labeled Leu-1 mAb and HRP-labeled streptavidin. Membranes were developed by chemiluminescence (ECL, Amersham Pharmacia).

Immunization of mice with T-dependent (TD) and -independent (TI) antigens

To study the antibody response to TD and TI antigens, 7–8 week-old shCD5EU/Tg and non-transgenic littermates were used and immunized i.p. under different experimental conditions. For induction of anti-human CD5 and CD6 antibody responses, mice were primed with 25 μg of rshCD5 or rshCD6, in complete Freund’s adjuvant (CFA, Sigma-Aldrich, UK) and boosted three weeks later with the same amount of protein in incomplete Freund’s adjuvant (IFA). Two weeks after the boosting mice were bled and their sera analyzed by ELISA using rshCD5 or rshCD6 as the coating antigen (see above).

For induction of anti-trinitrophenyl (TNP) antibodies mice were given 50 μg of TNP<sub>2</sub>-KLH (as TD antigen) in 400 μL of PBS in CFA at day 0 and with vehicle (PBS) at day 14, TNP<sub>2</sub>-LPS (as type 1 TI antigen) or TNP<sub>2</sub>-Ficol (as type 2 TI antigen) in 400 μL PBS. Antibigen-conjugated TNP haptenes were provided by Biosearch Technologies, Inc. (USA). Sera from immunized mice were collected at days 0, 7 and 14 (for TI response) or 0, 7, 14 and 21 (for TD response) days after the primary immunization and stored at −20°C until analysis.

Flow cytometry analysis of mouse lymphocyte subpopulations

The following mAb were used to characterize lymphocyte subpopulations in mice: Fluorescein isothiocyanate (FITC)-labeled anti-mouse CD4 (eBioscience, US), B220 (eBioscience), BP-1 (eBioscience), IgD (eBioscience), CD21 (7G6, eBioscience) and CD62L (Tombo Biosciences); Phycoerythrin (PE)-labeled anti-mouse CD23 (eBioscience), CD3<sub>δ</sub> (eBioscience), B220 (eBioscience), NK1.1 (eBioscience), CD5 (eBioscience), CD43 (BD Biosciences), CD11b (M1/70, eBioscience), CD93 (AA 4.1), IgD (eBioscience), CD4 (L3T4), CD44 (BD Biosciences); PerCP-Cy5.5-labeled anti-mouse CD25 (BD Biosciences), CD5 (BioLegend) and CD19 (eBioscience); Allophycocyanin (APC)-labeled anti-mouse CD24 (M1/69), CD3e (eBioscience), IgM (eBioscience) and CD25 (eBioscience); AlexaFluor 680-labeled anti-mouse IgM (eBioscience); AlexaFluor700 labeled anti-mouse CD8 (53-6-7); APC-Fluo 780-labeled anti-mouse B220 (BioLegend); anti-mouse IL-10 (JES5-16E3); Pacific blue-labeled anti-mouse B220 (BioLegend), GR1 (BD Biosciences) and CD11b (M1/70).

For staining, cell suspensions from spleen, lymph node and thymus were obtained using a cell strainer (50 μm). Splenocytes were depleted of erythrocytes by lysis with NH<sub>4</sub>Cl. Mouse peritoneal cells were obtained from peritoneal lavage with 4 mL PBS supplemented with 2% FCS and 0.01% sodium azide. Before surface staining with predetermined optimal concentrations of each mAb, cell samples (1×10<sup>6</sup>) were blocked by incubation with anti-CD16/32 2.4G2 mAb (Mouse BD Fc Block) for 30 min at 4°C.

For IL-10 intracellular staining, cells were stimulated with 50 ng/ml PMA, 500 ng/ml ionomycin (Sigma-Aldrich) and LPS (10 μg/ml, Escherichia coli serotype 0111:B4; Sigma-Aldrich) in the presence of Golgi-stop (moneisin 2 μM; eBioscience) for 4 h at 37°C, in 96-well v-bottom plates. After surface staining with anti-B220, anti-CD5 and anti-CD1d antibodies, cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD Pharmingen), according to the manufacturer’s instructions, and stained with PE-conjugated mouse anti-IL-10 mAb.

For FoxP3 intracellular staining, cells were stained with the PE-labeled anti-mouse/rat Treg Staining Kit (eBioscience), according to the manufacturer’s instructions. Briefly, 1×10<sup>6</sup> cells in suspension were stained with anti-CD4 and anti-CD25 antibodies and incubated with Fixation/Permeabilization Solution 18 h at 4°C. After this incubation, cells were washed twice with Permeabilization Buffer and incubated with anti-FoxP3 (Clone EJk-16s) 30 min at 4°C.

Nine-color flow cytometry was performed on a BD FACSCanto flow cytometer (Becton Dickinson, US). Each analysis shown
were immunized once at the base of the tail with 150 μg of collagen II in a final volume of 150 μl. Clinical evaluation of arthritis severity was performed as described [30]. For radiological studies, mice were anesthetized by i.p. injection of a mixture containing 50 mg/kg ketamine (Ketolar; Parke-Davis), 200 μg/kg atropine sulfate (Braun Medical, Spain), and 4 mg/kg diazepam (Roche, Spain). X-ray pictures were obtained using a CCX Rx ray source of 70 Kw with an exposure of 90 ms (Trophy Iris X-Ray System; Kodak, Spain). The radiological signal was digitalized with a Trophy RVG Digital Imaging system and analyzed using the Trophy Windows software. The severity of CIA was quantified radiologically with a graded scale according to the presence of five different radiological lesions (soft tissue swelling, juxtaarticular osteopenia due to alterations in bone density, joint space narrowing or disappearance, marginal erosions, and periosteal new bone formation). The extension of every individual lesion (local: affecting one digit or one joint in the carpus; diffuse: affecting two or more digits and/or two or more joints in the carpus) was graded from 0 to 1 as follows: 0, absence; 1/2, local; 1, diffuse. To clearly establish the radiological score in each paw, plain radiographs were assessed using a magnifying glass. Then, each paw was graded from 0 to 5, giving a maximum possible score of 20 for each mouse.

Experimental autoimmune encephalomyelitis (EAE) model

C57Bl/6 non-transgenic and shCD5E\(\text{m}\)Tg mice were immunized with a single s.c. injection of 130 μg of MOG35–55 peptide (BioSynthesis, USA) emulsified in CFA (Difco, supplemented with 400 μg/mL of Mycobacterium tuberculosis) on day 0, followed by one i.p. injection of 200 ng pertussis toxin (LIST Biologicals, USA) on day 0 and another on day 2 [31]. EAE symptoms were monitored daily for 30–35 days using a standard clinical score illustrated by Figure 1D, a 52-kDa band was detected in shCD5E\(\text{m}\)Tg mice sera, which was absent from that of non-transgenic littermates. The serum levels of shCD5 expressed by shCD5E\(\text{m}\)Tg mice were further analyzed by sandwich ELISA and were shown to be in the ~10–100 ng/mL range (Fig. 1C).

Further confirmation on the transgenic expression of shCD5 was obtained from the demonstration that shCD5E\(\text{m}\)Tg mice were tolerant to exogenously administered purified rshCD5, but not to rshCD6. To evaluate this, the titers of anti-shCD5 or anti-shCD6 antibodies in shCD5E\(\text{m}\)Tg mice immunized with two consecutive doses (25 μg each) of either rshCD5 or rshCD6 were analyzed by ELISA two weeks after the second immunization. As shown in Figure 1D, sera from shCD5E\(\text{m}\)Tg mice immunized with rshCD5 showed very low antibody levels against rshCD5, compared with those of non-transgenic mice sera. The specificity of the anti-CD5 antibody response was demonstrated by the lack of detection of antibodies reactive to both structurally similar (rshCD6) and unrelated (BSA) proteins. In contrast, when immunized with rshCD6 both shCD5E\(\text{m}\)Tg mice and non-transgenic mice showed very low antibody levels against rshCD5, compared with those of non-transgenic mice sera. The specificity of the anti-CD5 antibody response was demonstrated by the lack of detection of antibodies reactive to both structurally similar (rshCD6) and unrelated (BSA) proteins. In contrast, when immunized with rshCD6 both shCD5E\(\text{m}\)Tg mice and non-transgenic mice showed very low antibody levels against rshCD5.
Figure 1. Generation and characterization of human soluble hCD5 transgenic mice (shCD5E\textsubscript{Tg}). A) Structure of the plgHSV40shCD5 targeting vector. The cDNA sequence for shCD5 was inserted as Xhol-Apal in between the promoter and polyA sequence of the plg vector and then isolated as Scal-ApalI fragment for oocyte injections. B) Western blot analysis of human CD5 immunoprecipitates from transgenic (shCD5E\textsubscript{Tg}) and non-transgenic mice (NonTg) sera. The anti-CD5 Cris-1 mAb coupled with CNBr-activated Sepharose beads was used as immunoprecipitating agent. Western blotting was then carried out using the Leu-1 mAb plus HRP-labeled anti-mouse Ig. As a positive control, purified rshCD5 (50 ng) was included. C) ELISA detection of shCD5 in sera from shCD5E\textsubscript{Tg} mice. Sera from transgenic (shCD5E\textsubscript{Tg}, white) and non-transgenic littermates (NonTg, black) mice were analyzed by sandwich ELISA using Cris-1 and biotin-labeled Leu-1 as capture and developing mAbs, respectively. A standard rshCD5 curve was also analyzed in parallel to quantify results. D–E) shCD5E\textsubscript{Tg} mice are tolerant to exogenously administered rshCD5 but not rshCD6. shCD5E\textsubscript{Tg} mice and wild-type littermates were immunized twice with rshCD5 (D) or rshCD6 (E) (25 \textmu g) in Freund’s adjuvant (complete and incomplete, sequentially) within a 3-week interval. Mouse sera were collected 2 weeks after the boosting and added to ELISA plates coated with purified rshCD5, rshCD6 or BSA, then developed with a HRP-labeled anti-mouse IgG. Values represent the mean OD 450 nm values ± SD obtained in triplicate determinations for each sample (five mice per group). The total concentration of IgG was similar for both groups.

doi:10.1371/journal.pone.0084895.g001
shCD5EμTg mice exhibit normal proportions of major T and B cell subpopulations and developmental stages

To investigate the phenotype of shCD5EμTg mice regarding lymphocyte development and homeostasis, the total cell numbers and percentages of major lymphocyte subpopulations were analyzed in the thymus, lymph node, bone marrow, peritoneum and spleen. As shown in Figure 2, total cell numbers were not significantly different in the thymus, bone marrow or lymph node of shCD5EμTg mice compared with non-transgenic littermates, although the number of cells in peritoneum was significantly higher in shCD5EμTg mice; this increase could not be ascribed to any single population, as relative percentages of different cell subpopulations remained unchanged (data not shown). A higher number of cells was also observed in the spleen of shCD5EμTg mice although this did not reach statistical significance.

Further analysis of major T cell subsets (CD4+ and CD8+) from secondary lymphoid organs (lymph nodes and spleen) did not detect any gross abnormalities in lymphocyte subpopulation percentages of shCD5EμTg mice compared with non-transgenic littermates (Fig. S3A and B). A similar scenario was observed in thymus, where none of the different T cell developmental stages (DN1–DN4, DP, SP CD4+, SP CD8+) appeared to be affected (Fig. S3C and D).

B lymphocyte subsets from peripheral (spleen and peritoneum) and central (bone marrow) organs were also analyzed. As shown in Figure 3A, a significant decrease in the percentage of the transitional 1 (T1, IgMhi IgDlo CD93/AA4+ CD23−) and 2 (T2, IgMhi IgD+ CD93/AA4+ CD23+) cells as well as an increase in marginal zone B cells (MZB, IgM hi IgDlo CD93/AA4lo CD232) were detected in the spleen of shCD5EμTg mice compared with non-transgenic littermates. No significant differences were observed between shCD5EμTg and non-transgenic mice regarding the transitional 3 (T3, IgMhi IgDlo CD93/AA4+ CD23−), follicular I (FOLI, IgMhi IgDhi CD93/AA4+ CD21+), follicular II (FOLLII, IgMhi IgDhi CD93/AA4+ CD21/35lo) and MZ precursor (MZP, IgMhi IgDhi CD93/AA4+ CD21/35hi) cells (Figs. S4 and 5A). In a similar way to what was observed with T cell development, we did not find any major differences in B cell developmental stages in the bone marrow (Pre/pro-B, early pro-B, pro-B and pre-B cells) (Fig. S6).

However, as shown in Figure 3B and Figure S5B, analysis of peritoneal B cells showed a significant decrease in the percentage of B1a cells (B220+ IgMhi IgDlo CD5+) and a smaller, albeit significant, increase in the percentage of B1b cells (B220+ IgMhi IgDhi CD5−). No differences were observed in mature B2 cells (B220+ IgMhi IgDhi CD5−).

Taken together, phenotypical analysis of shCD5EμTg mice indicates that expression of shCD5 does not induce gross alterations on T and B cell development, and that the only abnormalities observed affect certain B cell subsets from spleen (T1, T2, MZB) and peritoneum (B1a, B1b).

shCD5EμTg mice display reduced proportions of B and T lymphocyte subsets with regulatory/suppressor function

Given that CD5+ B cells appeared to be reduced in shCD5EμTg mice, a subset of IL-10 secreting B cells with a regulatory/suppressor function, known as B10 cells (B220+ CD1dhi CD5+ IL10+), was further analyzed. As shown in Figure 4A and Figure S7A, B10 cells were significantly decreased in both peritoneal lavage and spleen samples from shCD5EμTg mice compared with non-transgenic littermates.
suggesting that intact CD5-mediated interactions are needed for the maintenance of this subpopulation.

It has recently been reported that CD5 expression regulates the generation and/or function of T regulatory cells (Tregs) [7,36]. Since shCD5 might interfere with putative ligand binding of endogenous CD5 expressed on T lymphocytes, we investigated whether changes in Treg cell numbers could be detected in primary and secondary lymphoid organs of shCD5E mice. As shown in Figure 4B and Figure S7B, no differences in the percentage or number of Treg (CD4+CD25+FoxP3+) cells were observed in the thymuses of shCD5E mice. However, a significant reduction in the percentage of Tregs was observed in the lymph nodes of these mice compared with their non-transgenic littermates.

NKT cells (NK1.1+CD3+) constitute another CD5+ regulatory cell subset. As shown in Figure 4C and Figure S7C, and contrary to what was observed for B and T cell regulatory subsets, NKT cells were found to be increased in spleens from shCD5E mice compared with non-transgenic littermates. Overall, the data indicate that shCD5E mice present alterations in different regulatory cell subpopulations, which could have important consequences for the immune response of these mice.

To rule out random events of transgenesis and confirm that the observed changes in regulatory cell subpopulations were caused by increased circulating levels of shCD5, similar cell analyses were performed on wild-type C57Bl/6 mice treated with repeated i.p. infusions of purified rshCD5 protein (1,25 mg/kg, every other day for two weeks). As shown in Figures 5A and 5B, B1a and B10 cells were significantly reduced in the peritoneum, but not in the spleen of rshCD5-treated mice compared with control mice. In addition, Treg cells were found to be reduced in the spleen but not in the lymph nodes of wild-type mice injected with rshCD5 (Fig. 5C). Finally, analysis of NK1.1+ cells, showed an increase in NKT cells (NK1.1+, CD3+) in the spleen of rshCD5-treated mice (Fig. 5D). These data indicate that sustained treatment of wild-type mice with exogenous rshCD5 can induce similar phenotypical changes to those observed in shCD5E mice, unequivocally ascribing the effects of transgenesis to the presence of circulating shCD5.
Antibody response to T-independent-1 antigens is enhanced in shCD5E\(_{m}\)Tg mice

To further evaluate the functional consequences of the lymphocyte subset alterations observed in shCD5E\(_{m}\)Tg mice, in vivo antibody responses to different T-dependent and -independent antigens were analyzed. Transgenic shCD5E\(_{m}\)Tg mice and non-transgenic littermates were immunized i.p. with the hapten trinitrophenol (TNP) conjugated to a T-dependent (TD) antigen (keyhole limpet hemocyanin; TNP\(_{5}\)-KLH), a T-independent type 1 (TI-1) antigen (LPS; TNP\(_{0,3}\)-LPS) and a T-independent type 2 (TI-2) antigen (Ficoll; TNP\(_{65}\)-Ficoll), and serum levels of specific anti-TNP antibodies analyzed by ELISA. No significant differences were observed for anti-TNP antibody levels in shCD5E\(_{m}\)Tg mice immunized with TD antigen (TNP\(_{5}\)-KLH), with the exception of IgG1 antibodies at day 21 post-immunization, which were significantly higher in transgenic mice (Fig. 6A and Fig. S8A). However, a trend towards higher levels of IgM antibodies was also observed in shCD5E\(_{m}\)Tg mice. Regarding the response to the TI-1 antigen (TNP\(_{0,3}\)-LPS), higher levels of anti-TNP antibodies were also observed for shCD5 transgenic mice in all the Ig isotypes tested, at nearly all time points (Fig. 6B and Fig. S8B). By contrast, levels of antibodies in mice immunized with the
TI-2 antigen (TNP-Ficoll) appeared to be unchanged in shCD5E mTg mice at all time points, for all the different Ig isotypes analyzed (Fig. 6C and Fig. S8C). These results suggest that the B cell antibody response against TI-1 antigens – and, to a lesser extent, against TD antigens – is enhanced in shCD5E mTg mice compared with that of non-transgenic littermates.

Experimentally induced autoimmune diseases are more severe in shCD5E mTg mice

To gain insight into the in vivo immune response to auto-antigens in shCD5E mTg mice, two different models of experimentally induced autoimmune disease were evaluated. First, collagen-induced arthritis (CIA) in (B6 × DBA/1) F1 mice, a well-established model of T-cell mediated autoimmune disease resembling rheumatoid arthritis, was used. As shown in Figure 7A and Figure 7B, increased severity of arthritis symptoms (oedema, joint narrowing, marginal erosion, osteopenia) was observed in shCD5E mTg mice compared with non-transgenic littermates. Moreover, demyelination was also increased in shCD5E mTg mice (Fig. 7C). Altogether, the data show that shCD5E mTg mice display more severe forms of experimentally induced autoimmune disease in models developed against different auto-antigens.

Tumor growth is slowed in shCD5E mTg mice

Since autoimmune and anti-tumoral immune responses are both directed mainly against self-antigens, the in vivo response of shCD5E mTg mice to autologous tumor antigens was evaluated. A melanoma B16 cell model (syngeneic with C57Bl/6 mice) was chosen, and tumor growth was recorded over time. As shown in Figure 8A, B16 tumors grew significantly more slowly in shCD5E mTg mice compared with their non-transgenic littermates. Taking these data into account, a potentially improved response of shCD5E mTg mice to i.v. injected B16 cells was also evaluated. Experimental metastasis assays revealed a decrease in the number of lung metastases observed in shCD5E mTg compared with non-transgenic littermates (Fig. 8B), which was close to significance (p = 0.09).

To evaluate whether administration of exogenous rshCD5 to non-transgenic mice could also delay tumor growth, wild-type C57Bl/6 mice s.c. implanted with B16 cells were treated with vehicle (PBS+glycerol) or rshCD5 (1.25 mg/kg) administered
every 48 h from the day of tumor cell injection. A single dose of chemotherapy (vincristine 0.5 mg/kg, doxorubicin 3.3 mg/kg) was also administered at day 3 after tumor cell injection for both groups. As shown in Figure 8C, tumor progression was slowed in mice treated with chemotherapy plus rshCD5, compared with mice treated with chemotherapy plus vehicle. Altogether, these results suggest that increased circulating levels of shCD5 delay progression of melanoma cells in mouse tumor models.

Discussion

Important immunomodulatory properties have been ascribed to CD5 during lymphocyte development and activation [37], which
Figure 7. Exacerbated autoimmune disease in shCD5E\textsubscript{Tg} mice. A) Analysis of CIA induction in (DBA\textsubscript{B6})\textsubscript{F1}\times shCD5E\textsubscript{Tg} mice and non-transgenic littermates. 7–8 week old mice were immunized s.c. near the base of the tail with 100 \textmu l of antigen (2 mg/ml type II bovine collagen) emulsified in CFA plus Arthrogen-CIA adjuvant. Radiological signs were scored weekly for each mouse and results for each group averaged to determine overall clinical score. B) IL-6 levels were determined by real time RT-PCR in joint tissue, normalizing results to GAPDH expression levels. Results are expressed in arbitrary units (A.U.). * \( p = 0.05 \). C and D) Antibodies against type II collagen were measured by ELISA in the sera of (DBA\textsubscript{B6})\textsubscript{F1}\times shCD5E\textsubscript{Tg} transgenic mice and non-transgenic littermates. Antibody determination included total IgG (C) and IgG1 (D). Results are expressed as OD 450 nm. E) Analysis of EAE induction in shCD5E\textsubscript{Tg} and non-transgenic mice. 8–10 week old mice were administered s.c. with 200 \textmu l of antigen (50 \mu g MOG peptide) in CFA. At the time of immunization and 48 hs later, 200 ng of Pertussis toxin were also injected i.p. Clinical score was determined daily and it represents the average value for each mice, where 0 = no disease; 0.5 = partially motionless tail; 1 = motionless tail; 2 = ataxia; 3 = loss of mobility in one limb; 4 = loss of mobility in back limbs; 5 = moribund. Graphs show the comparison between clinical scores of shCD5E\textsubscript{Tg} (\( n = 5 \)) and non-transgenic mice (\( n = 10 \)), \( p = 0.05 \) (Two-way ANOVA test). F) Demyelination and infiltration scores, as detected by solochrome cyanin and hematoxylin and eosin staining, respectively. ** \( p = 0.02 \). doi:10.1371/journal.pone.0084895.g007
make this receptor a potential target for immunotherapeutic approaches. Although no CD5 deficiency has been reported in humans, studies in CD5−/− mice have provided valuable information in this regard, showing CD5 to act as a negative modulator of antigen-driven activation of T cells (and certain B cells) [15,16]. Considering that genetic deletion or silencing of CD5 in humans would be fraught with both technical and ethical problems, induction of sustained circulating levels of a soluble form of CD5 was devised as an alternative strategy of hindering this receptor in a functional and reversible way. In order to avoid repeated infusions of expensive purified protein and also to maintain stable levels of soluble CD5, a new shCD5-expressing transgenic mouse line (shCD5EgTg) was generated, which may serve as a test-bed for future applications in the clinic.

The shCD5EgTg mice herein reported display modest, albeit readily detectable and sustainable serum levels of shCD5 from early stages of development, making the mice tolerant to the human protein. To develop this transgenic mouse line, advantage was taken of the inter-species conservation of the receptor-ligand interactions existing between mouse and human CD5, something which had already been reported for the closely related receptor CD6 [33,38]. Indeed, shCD5 is able to interact with the as yet undefined CD5 ligand/s, thus likely acting as a decoy receptor capable of impairing the functional consequences of receptor-ligand interactions mediated by membrane-bound CD5. Thus, shCD5EgTg mice would have a lower threshold for antigen-specific receptor-mediated activation and subsequently, an enhanced immune response. This is confirmed in this work, where shCD5EgTg mice are shown to have an increased response against different types of antigens.

Transgenic shCD5EgTg mice were shown to display an enhanced in vivo antibody response to certain soluble antigens, particularly TD and TI-1 antigens. Indeed, induction of two different experimental autoimmune diseases (CIA and EAE) resulted in a more severe outcome for shCD5EgTg mice compared with non-transgenic littermates. The increase in disease severity was measured not only by clinical score, but also through determination of pro-inflammatory cytokine levels and autoantibody responses. While no CIA studies have been carried out in CD5−/− mice, it has been recently shown that CD5−/− and CD5ACK1IBB mice (mice expressing a truncated and functionally defective form of CD5) immunized with high doses of MOG show more severe forms of EAE than wild-type mice [39]. Thus, physical deletion and functional knock-down of CD5 both appear to lead to a similar outcome with regard to autoimmune responses.

Both autoimmune and anti-tumor responses are directed mainly towards autologous antigens. Indeed, syngeneic B16 melanoma tumors developed in shCD5EgTg and in non-transgenic mice, but grew at a slower rate in shCD5EgTg mice, which also showed a decreased number of lung metastases following i.v. injection of tumor cells. These results are also in agreement with previous studies carried out in CD5−/− mice, in which B16F10 tumors grew more slowly compared to those in wild-type mice [40].

Phenotypical analysis of shCD5EgTg mice did not reveal any gross alterations in major lymphocyte subpopulations. However, careful subpopulation analysis showed a decrease in T and B cell subsets with regulatory function, as well as an increase in NKT cells. It has been reported that generation of thymus-derived T cell subsets with regulatory function, as well as an increase in NKT cells, suggesting that the observed decrease in Treg cells is at the expense of inducible Treg (iTregs) cells. Another possibility is that

Figure 8. Delayed tumour growth in shCD5EgTg mice. A) shCD5EgTg mice (n = 16) and non-transgenic littermates (n = 15) were injected s.c. with 5 × 10^4 B16 melanoma cells. Tumour growth was recorded over time by measuring with a Vernier calliper. *** p = 0.0177. B) Experimental metastasis assay. Mice were injected i.v. with 1 × 10^7 B16 melanoma cells. Fifteen days later, mice were sacrificed, their lungs removed and the metastases on the surface counted. p = 0.0994. C) Non-transgenic C57Bl/6 mice (n = 5 for each group) were injected with B16 cells as before. Chemotherapy (vincristine 0.5 mg/kg, Doxorubicin 3.3 mg/kg) was administered i.p. at day 3 after tumor cell injection. Additionally, rshCD5 (25 μg) or vehicle was injected i.p. every 48 hs for the duration of the experiment (20 days). ** p = 0.0083. doi:10.1371/journal.pone.0084895.g008
cross-linking of membrane-bound CD5 is not necessary for T cell development in the thymus, as it has been reported that the cytoplasmic region alone might be sufficient for intrathymic selection [41]; this is consistent with the authors mentioning the lack of CD5L expression in the thymus. However, the authors also point out that CD5-CD5L interactions would indeed be important in the periphery, which is in agreement with our results. Thus, although the extracellular region of CD5 might be dispensable for some of its functions, it is still necessary for modulation of antigen-specific receptor signalling, at least in the periphery.

B10 cells were also decreased in shCD5EμTg mice. The same subpopulation is also decreased in CD5−/− and in CD5ΔCKIIBD mice (data not shown), supporting an important role for intact CD5 function in the maintenance of this subpopulation [42]. Indeed, it has been reported that CD5 expression is required for IL-10 production by Bregs, acting as a survival factor [42]. In a similar way, intact CD5 function might be required for other CD5-expressing cell types, such as NKT cells. It is also possible that NKT cell number and/or activity could be influenced indirectly by regulatory T and/or B cells, as has been speculated previously [43].

Importantly, the observed changes in regulatory lymphocyte subpopulations were not due to random transgene insertion, since the phenotype could be reproduced in wild-type C57Bl/6 mice by repeated administration of exogenous rshCD5 protein. These results indicate that there is a causal relationship between the presence of increased circulating levels of shCD5 and changes in cell subpopulation dynamics, particularly in those cell types with high membrane-bound CD5 expression.

The results obtained in functional assays (autoimmunity and tumor models) tie in well with the decrease in lymphocyte subpopulations with regulatory/suppressor function observed in shCD5EμTg mice. Regulatory cells have been shown to suppress activation of the immune system, and a decrease in these cells would then be expected to enhance the immune response to self and non-self antigens, particularly when coupled with an increase in NKT cells. The latter cells are able to generate large quantities of cytokines that can quickly modulate and polarize the immune response. However, a decrease in Treg cells by itself has been reported to slow down tumor growth [44].

Although the main intention of these experiments was to characterize the immune response in shCD5EμTg mice, these mice were also developed to test potential future clinical applications of shCD5. As such, our results suggest a beneficial effect of shCD5 in the treatment of tumors, through an enhancement in the in vivo anti-tumor response. Cancer treatment, however, is usually a combination of different drugs and/or therapies; if shCD5 were ever to be used in the treatment of tumors, it would probably be as an adjuvant to an established therapy such as chemotherapy. Our results show that exogenous repeated administration of rshCD5 in combination with chemotherapy improved the performance of chemotherapy alone in mice, suggesting that this protein might be used as an adjuvant of standard chemotherapy.

In conclusion, impairment of CD5/CD5L interactions by shCD5 results in an enhancement of the immune response against autologous antigens. This enhancement could be due to the observed changes in lymphocyte subpopulations with regulatory function; another possibility is that, considering that CD5 is a negative regulator of T and B cell responses, impairment of its function could also result in enhanced activation of effector T and B cells. Although it is not clear which mechanism is prevalent, it is likely that both effects contribute to the overall phenotype in a combined manner. The results therefore suggest that shCD5 is an immunomodulatory target that could be used in the treatment of diseases which would benefit from an enhancement of a normal or depressed immune response, such as cancer.

**Supporting Information**

**Figure S1** Interspecies cross-reactivity of receptor-ligand interactions mediated by CD5 and CD6. Mouse (top panels) and human (bottom panels) PBMCs (1.5×10⁶) were cultured for 72 hs in the presence (bold line) or absence (fine line) of PMA 100 ng/ml and Lonomycin 1 μg/ml. Cells were then incubated with 1 μg biotin-labeled shCD5 (left panels) or shCD6 (right panels) for 1 hr, and developed with FITC-conjugated streptavidin for further analysis by flow cytometry. Results shown correspond to the gated lymphocyte subpopulation. (TIF)

**Figure S2** Identification of shCD5EμTg mice by PCR. Following PCR amplification of shCD5 from tail DNA, a PCR product of the expected size (450 bp) was detected in transgenic mice. A fragment of 150 bp corresponding to the LIE gene was also amplified as an internal control for the PCR. (TIF)

**Figure S3** Analysis of major T lymphocyte subpopulations and development in shCD5EμTg mice. Lymph node (A) and spleen (B) cells were stained with anti-CD4 and anti-CD8 specific antibodies to identify CD4−, CD8−, or CD4−CD8− (mostly B cells). C) To analyze the effect of shCD5 expression on T cell development, thymocytes were stained with anti-CD4 and anti-CD8 antibodies to identify DN, DP, CD4+SP and CD8+SP cells. D) To analyze the effect of shCD5 expression on early T cell development, thymocytes were stained with anti-CD44 and anti-CD25 antibodies to distinguish between DN1 (CD44+CD25−), DN2 (CD44+CD25+), DN3 (CD44−CD25+) and DN4 (CD44−CD25−) cells. (TIF)

**Figure S4** Flow cytometry analysis of B lymphocyte subpopulations in shCD5EμTg mice. To analyze peripheral B cell subsets from spleen and peritoneum, we used a gating strategy adapted from Cariappa et al [45]. Transitional 3 (T3) and follicular I (FOLI) cells can be distinguished in the IgMlowIgDhigh gated subpopulation using the CD21/33 and CD93/AA4 markers. Finally, the IgMhighIgDhigh gated subpopulation allows for the detection of follicular II (FOLII) cells and marginal zone precursors (MZP) based on the surface expression of AA4 and CD21. (TIF)

**Figure S5** Gating for flow cytometry analysis of B lymphocyte subpopulations in shCD5EμTg mice. A) Representative dot plots showing the gating strategy for B cell subpopulation analysis. First, cells were gated for IgM and IgD; subsequently, T1, T2 and MZ cells were detected in the IgMlowIgDlow gate by staining with CD93/AA4 and CD93. Similarly, gated on IgMlowIgDhigh, FOL I and T3 cells could be distinguished according to CD21 and CD93/AA4 staining. Finally, gating on IgMhighIgDhigh allowed for detection of FOL II and MZP based on CD93/AA4 and CD21/35 staining. B) Representative dot plots showing the gating strategy for B1 and B2 subpopulation analysis. Gated on IgMhighIgDlow, B1a and B1b cells can be distinguished based on their CD5 expression, while B2 cells are IgMhighIgDhigh. (TIF)
Figure S6 Analysis of B lymphocyte development in shCD5E Tg mice. To analyze the effect of shCD5 in B lymphocyte development, bone marrow cells were stained with a series of antibodies (CD43, B220, CD24 and BP-1) to identify the different B cell subsets at various stages of maturation. From the gated CD43+B220+ subpopulations, pre-pro-B cells (CD24lowBP-1+), early pro-B cells (CD24+BP-1+), late pro-B cells (CD24+BP-1+), and pre-B cells (CD24highBP-1+) could be identified based on the expression of CD24 and BP-1.

Figure S7 Gating for flow cytometry analysis of regulatory lymphocyte subpopulations in shCD5E Tg mice. A) Representative dot plots showing the gating strategy for B10 cell analysis. Cells gated on CD1d+CD5+ were analyzed for B220 and IL-10 staining; B220+ cells were considered as B10 cells. B) Representative dot plots showing the gating strategy for Treg cell analysis. Gated on CD4+ cells, CD25+FoxP3+ cells were considered as Treg cells. C) Representative dot plots showing the gating strategy for NKT cell analysis, CD3+NK1.1+ cells were considered as NKT cells.

Figure S8 shCD5E Tg and non-transgenic mice IgM response to immunization with T-dependent and T-independent (type 1 and type 2) antigens. Mice were immunized i.p. with 50 μg TNP5-KLH (A), TNP0.3-LPS (B) or TNP65-Ficoll (C) in 200 μl PBS, as examples of TD, TI type 1 and TI type 2 antigens, respectively. Sera from immunized mice were collected at days 0, 7 and 14 (for TI response) or 0, 7, 14 and 21 (for TD response) after the primary immunization and levels of TNF-specific antibodies determined by ELISA. IgM levels are expressed as OD 450 nm values. The bars represent the average value for each group. ** p<0.05.

Figure S9 Exacerbated autoimmune disease in shCD5E Tg mice. A) Radiological signs (edema, joint narrowing, marginal erosions and osteopenia) were scored at week 8 for each mouse as described in the Materials and Methods section. B) Cytokine mRNA levels were determined by real time RT-PCR in joint tissue, normalizing results to GAPDH expression levels. Results are expressed in arbitrary units (A.U.). C) IgG1 antibodies against type II collagen were measured by ELISA in the sera of shCD5E Tg transgenic mice and non-transgenic littermates at weeks 0 and 8. Results are expressed as OD 450 nm.

Author Contributions
Conceived and designed the experiments: RF VGM JM RM RC CR GS. Performed the experiments: RF VGM JS RN KSC JM RM. Analyzed the data: RF VGM JP JM MRA CR GS PE. Contributed reagents/materials/analysis tools: JM RM CR PE. Wrote the paper: RF VGM JM RA CR GS PE.

References
1. Resnick D, Pearson A, Krieger M (1994) The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci 19: 5–8.
2. Rodamalas B, Buanse S, Braygo-Nsison E, Sarrias MR, Lozano F, et al. (2007) Expression, purification and crystallization of human CD5 domain III, a nano-scale crystallization example. J Struct Biol 159: 144–148.
3. Martinez VG, Moestrup SK, Holmskov U, Mollenhauer J, Lozano F (2011) The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis. Pharmacol Rev 63: 967–1000.
4. Sarrias MR, Gronlund J, Padilla O, Madsen J, Holmskov U, et al. (2004) The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol 24: 1–37.
5. Berland R, Wortis HH (2002) Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20: 253–300.
6. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, et al. (1999) Increased numbers of thymic and peripheral CD4+CD5- cells in the absence of CD5 signaling. Eur J Immunol 29: 2233–2247.
7. Ordonez-Rueda D, Lozano F, Sarrias MR, Abian J, Garcia-Zepeda EA, et al. (2009) Increased numbers of thymic and peripheral CD4+ CD5-FoxP3+ cells in the absence of CD5 signaling. Eur J Immunol 39: 2233–2247.
8. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, et al. (2008) A conserved protein module of the innate immune system. Nat Struct Mol Biol 15: 334–337.
9. Burgess RE, Yamamoto M, Prasad KV, Rudd CE (1992) CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and proline-rich kinases p56lck and p59fyn. Proc Natl Acad Sci U S A 89: 9311–9315.
10. Huang HJ, Jones NH, Strominger JL, Herzenberg LA (1987) Molecular cloning of Ly-1, a membrane glycoprotein of mouse T lymphocytes and a subset of B cells: molecular homology to its human counterpart Leu-1/IT (CD5). Proc Natl Acad Sci U S A 84: 204–208.
11. Jones NH, Clabby ML, Dialynas DP, Huang HJ, Herzenberg LA, et al. (1986) Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature 323: 346–349.
12. Lozano F, Sinarro M, Calvo J, Vila JM, Padilla O, et al. (2000) CD5 signal transduction: positive or negative modulation of antigen receptor signaling. Crit Rev Immunol 20: 347–356.
13. Gruppen JL, Baroja ML (1986) Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3. J Immunol 137: 1816–1821.
14. Ledbetter JA, Martin PJ, Spooner CE, Wolfs D, Tsu TT, et al. (1985) Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol 135: 2331–2336.
15. Tarakhovsky A, Kanner SB, Honbach J, Ledbetter JA, Muller W, et al. (1995) CD5 mediates signal transduction and thymocyte selection. Science 269: 535–537.
16. Bikah G, Carey J, Gaalilla JR, Tarakhovsky A, Bonaduda S (1996) CD5-mediated negative regulation of antigen receptor-induced growth signals in B1 cells. Science 274: 1906–1909.
17. Azuma HS, DeJarnette JR, Huang K, Emmouns R, Park CS, et al. (2001) Fine tuning of TCR signaling by CD5. J Immunol 166: 5464–5472.
18. Calvo J, Places L, Equinoa G, Padilla O, Vila JM, et al. (1999) Identification of a natural soluble form of human CD5. J Biol Chem 274: 1517–1522.
19. Jamin C, Magadur G, Lamour A, Mackenzie L, Lydyard P, et al. (1992) Cell-free CD5 in patients with rheumatoid diseases. Immunol Lett 31: 79–83.
20. Kanno-Canals M, Font J, Garcia-Carrasco M, Calvo J, Places L, et al. (2001) High circulating levels of soluble scavenger receptors (CD5 and CD6) in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 40: 1056–1059.
21. Noh G, Lozano F (2001) Intravenous immune globulin effects on serum-soluble CD5 levels in atopic dermatitis. Clin Exp Allergy 31: 1932–1938.
22. Gimferrer I, Calvo M, Mittelbrunn M, Farnos M, Sarrias MR, et al. (2004) Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 173: 2262–2270.
23. Vera J, Ferrer R, Canadas O, Figueras M, Mota R, et al. (2009) The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A 106: 1506–1511.
24. Lenz SL (2009) CD5 sweetens lymphocyte responses. Proc Natl Acad Sci U S A 106: 1303–1304.
25. Ronchese F, Hausmann B, Hubele S, Lane P (1994) Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo. J Exp Med 179: 809–817.
26. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen ML, et al. (2001) Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7: 199–205.
27. Gimferrer I, Farnos M, Calvo M, Mittelbrunn M, Emrich C, et al. (2003) The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells. J Biol Chem 278: 8564–8571.
28. Sarrias MR, Padilla O, Monreal Y, Carrascall M, Abian J, et al. (2004) Biochemical characterization of recombinant and circulating human Spalhpa. Tissue Antigens 63: 335–344.
29. Alberola-Ila J, Places L, Cantrell DA, Vives J, Lozano F (1992) Intracellular events involved in CD5-induced human T cell activation and proliferation. J Immunol 148: 1287–1293.
30. Lopez-Hoyos M, Marquina R, Tamayo E, Gonzalez-Rojas J, Izuí S, et al. (2003) Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibodies in mice. Arthritis Rheum 48: 2353–2361.
31. Axtell RC, Webb MS, Barman SR, Raman C (2004) Cutting edge: critical role for CD5 in experimental autoimmune encephalomyelitis: inhibition of engagement reverses disease in mice. J Immunol 173: 2928–2932.
32. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK (2006) Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116: 2393–2402.
33. Wee S, Wang WC, Farr AG, Nelson AJ, Patel DD, et al. (1994) Characterization of a CD6 ligand(s) expressed on human- and marine-derived cell lines and marine lymphoid tissues. Cell Immunol 158: 353–364.
34. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK (2002) Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16: 219–230.
35. Wolf SD, Dittel BN, Harardottir F, Janeway CA Jr (1996) Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 184: 2271–2278.
36. Dasu T, Qualls JE, Tuna H, Raman C, Cohen DA, et al. (2008) CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immuno Lett 119: 103–113.
37. Soldevila G, Raman C, Lozano F (2011) The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. Curr Opin Immunol 23: 310–318.
38. Bowen MA, Bajrath J, D'Egidio M, Whitney GS, Palmer D, et al. (1997) Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol 27: 1469–1478.
39. Sestero CM, McGuire DJ, De SP, Brandley EC, Soldevila G, et al. (2012) CD5-dependent CK2 activation pathway regulates threshold for T cell energy. J Immunol 189: 2918–2930.
40. Talbott M, Franczekievicz K, Haouas H, Leclue Y, Benihoud K, et al. (2011) Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J Immunol 187: 102–109.
41. Bhandoola A, Bosseut R, Yu Q, Cowan ML, Friegenbaum L, et al. (2002) CD5-mediated inhibition of TCR signaling during intrathymic selection and development does not require the CD5 extracellular domain. Eur J Immunol 32: 1811–1817.
42. Gary-Gouy H, Harriague J, Bismuth G, Platez C, Schmitt C, et al. (2002) Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 100: 4537–4543.
43. Mauri C (2010) Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 22: 761–767.
44. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR (2013) Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 171: 36–45.
45. Cariappa A, Boboila C, Moran ST, Liu H, Shi RN, et al. (2007) The recirculating B cell pool contains two functionally distinct, long-lived, posttransitional, follicular B cell populations. J Immunol 179: 2270–2281.